Pathstone Holdings’s SAB Biotherapeutics SABS Stock Holding History

Pathstone Holdings’s Portfolio SABS Stock Details SABS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$198K	Hold	50,650	–	–	﹤0.01%	2237
2026 Q1	$194K	Hold	50,650	–	–	﹤0.01%	2114
2025 Q4	$189K	Hold	50,650	–	–	﹤0.01%	2117
2025 Q3	$102K	Hold	50,650	–	–	﹤0.01%	2269
2025 Q2	$88.9K	Hold	50,650	–	–	﹤0.01%	2128
2025 Q1	$68.9K	Hold	50,650	–	–	﹤0.01%	2169
2024 Q4	$192K	Hold	50,650	–	–	﹤0.01%	2179
2024 Q3	$137K	Hold	50,650	–	–	﹤0.01%	2226
2024 Q2	$157K	Hold	50,650	–	–	﹤0.01%	2190
2024 Q1	$230K	Sell	50,650 -1	-0%	-$6	﹤0.01%	2073
2023 Q4	$348K	Buy	+50,651	New	+$425K	﹤0.01%	1726

Other funds holding SABS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SSC

Spruce Street Capital New York $510M AUM

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Pathstone Holdings's SABS Position: Q2 2026 in Review

Pathstone Holdings held its SAB Biotherapeutics (SABS) position steady in Q2 2026 at 50,650 shares worth $198K. The position accounts for ﹤0.01% of the portfolio, ranked #2237.

Pathstone Holdings first reported a position in SABS in Q4 2023 and has held it in 11 quarters since. The position peaked at $348K in Q4 2023. 49 funds tracked by Wall St. Rank hold SABS as of Q2 2026.

Pathstone Holdings held 50,650 shares of SAB Biotherapeutics worth $198K as of Q2 2026.
Pathstone Holdings left its SAB Biotherapeutics share count unchanged in Q2 2026.
SAB Biotherapeutics made up ﹤0.01% of Pathstone Holdings's portfolio in Q2 2026, its #2237 holding.
Pathstone Holdings first reported a position in SAB Biotherapeutics in Q4 2023 and has held it in 11 quarters since.
Pathstone Holdings's SAB Biotherapeutics position peaked at $348K in Q4 2023.
49 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q2 2026.

Based on Pathstone Holdings's 13F filing for Q2 2026, filed 13 Aug 2026.